Welcome to our dedicated page for Atara Biotherapeutics news (Ticker: ATRA), a resource for investors and traders seeking the latest updates and insights on Atara Biotherapeutics stock.
Atara Biotherapeutics, Inc (Symbol: ATRA) is a pioneering company in the healthcare sector, specializing in the development of transformative therapies for patients combating serious diseases, including cancer, kidney disease, and autoimmune disorders. Founded in August 2012, Atara Biotherapeutics is driven by a mission to provide better treatment options for patients, inspired by Atara Ciechanover, who tragically passed away from cancer in 2012.
The company's research is founded on groundbreaking discoveries related to activin, myostatin, and other growth factors that can alter disease progression. Atara's innovative approach has led to the development of several promising product candidates:
- Pinta 745
- STM 434
- ATA 842
Moreover, Atara Biotherapeutics is collaborating with the prestigious Memorial Sloan Kettering Cancer Center (MSK) to develop three cutting-edge T-cell product candidates:
- Epstein-Barr Virus (EBV)-targeted Cytotoxic T Lymphocytes (CTLs)
- Cytomegalovirus (CMV)-targeted CTLs
- Wilms Tumor 1 (WT1)-targeted CTLs
These T-cell therapies are designed to tackle the underlying mechanisms of various diseases, offering hope for conditions that are currently challenging to treat.
Atara's product pipeline also includes Tab-cel, ATA188, and ATA3219 (CAR T platform). Each of these candidates targets specific mechanisms of disease, aiming to provide effective and innovative treatment solutions.
The company operates within the US healthcare sector, managing its business as a single operating and reportable segment focused on therapeutic development. Atara Biotherapeutics continues to make strides in its mission, marked by recent achievements and partnerships that underscore its commitment to improving patient outcomes.
Stay updated with the latest news and developments from Atara Biotherapeutics to gain insights into their ongoing projects and performance in the stock market.
Atara Biotherapeutics (ATRA) announced positive long-term overall survival (OS) data for tabelecleucel (tab-cel®) in patients with Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation. The analysis covered 50 patients from three studies, showing a 62% objective response rate and an 86% two-year survival rate. Atara plans to file a Biologics License Application (BLA) in Q3 2021 and a Marketing Authorization Application (MAA) in Europe in Q4 2021.
Atara Biotherapeutics (Nasdaq: ATRA) announced that its CEO Pascal Touchon and CMO AJ Joshi will participate in a fireside chat at the Virtual 33rd Annual ROTH Conference on March 16, 2021, at 4:30 p.m. EDT. The event highlights Atara's commitment to advancing T-cell immunotherapy for serious diseases like solid tumors and autoimmune disorders. A live webcast will be available on the company’s website, with an archived replay for 30 days after the event. Atara is developing therapies leveraging its allogeneic EBV T-cell platform, aiming to address high unmet medical needs.
Atara Biotherapeutics (Nasdaq: ATRA), a leader in T-cell immunotherapy, announced the grant of restricted stock units and stock options to new employees as part of its 2018 Inducement Plan. A total of 40,800 restricted stock units and 55,000 stock options will be distributed, vesting over four years contingent on continued employment. The stock options have a ten-year term with an exercise price set at $17.10 per share, the closing price on March 1, 2021. This initiative aligns with Nasdaq Listing Rule 5635(c)(4) to incentivize new talent.
Atara Biotherapeutics (Nasdaq: ATRA) reported its financial results for Q4 and full year 2020, highlighting key business milestones and future catalysts. The company anticipates a rolling BLA filing for tab-cel® in Q3 2021 and plans to submit an EU MAA for EBV+ PTLD in Q4 2021. With cash totaling $500.7 million as of December 31, 2020, Atara believes it can fund operations into 2023. However, the company reported net losses of $81.3 million for Q4 2020, compared to $78.5 million in Q4 2019, and R&D expenses increased to $244.7 million for the full year.
Atara Biotherapeutics (Nasdaq:ATRA) plans to release its fourth quarter and full year 2020 financial results on March 1, 2021, post market close. The company will host a conference call and webcast at 4:30 p.m. EST to discuss the results and provide a corporate update. Analyst participation is encouraged, with call-in options available for domestic and international callers. Atara focuses on T-cell immunotherapy, particularly in treating serious diseases like solid tumors and hematologic cancers using its allogeneic EBV T-cell platform.
Atara Biotherapeutics (Nasdaq: ATRA) announced advancements in its T-cell immunotherapy research at the TCT 2021 meeting, including data on its lead candidate, tab-cel®.
Key points include consistent therapeutic activity across tab-cel® production, clinical studies in EBV-related diseases, and the advancement of ATA3219, a next-generation CAR T therapy. Further, a novel testing solution for non-engineered therapies, developed with CareDx, aims to enhance therapeutic monitoring.
The company remains on track for a Biologics License Application in Q3 2021, based on promising interim trial data.
Atara Biotherapeutics (Nasdaq: ATRA) has announced six poster presentations at the upcoming Transplantation & Cellular Therapy (TCT) Meeting, occurring virtually from February 8-12, 2021. The presentations will focus on Atara's innovative allogeneic EBV T-cell platform, highlighting the mechanism of action of tabelecleucel (tab-cel®) and an assay for non-engineered T-cell therapies. Key posters include studies on tabelecleucel's clinical efficacy and the development of a new CAR-T therapy, ATA3219, without gene editing.
Atara Biotherapeutics (Nasdaq: ATRA) revealed its strategic priorities and progress at the upcoming J.P. Morgan Healthcare Conference on January 13, 2021. CEO Pascal Touchon emphasized significant advancements in 2020, particularly for its lead candidate tab-cel® for EBV-positive post-transplant lymphoproliferative disease. Key milestones include the completion of the BLA rolling submission and anticipated approvals in the U.S. and EU in 2022. Additionally, Atara plans to provide updates on ATA188 for progressive MS and CAR T programs throughout the year.
Atara Biotherapeutics (Nasdaq: ATRA) announced that CEO Pascal Touchon will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13 at 1:30 PM PST/4:30 PM EST. This event will showcase Atara's advancements in T-cell immunotherapy, particularly its allogeneic EBV T-cell platform aimed at treating serious diseases like solid tumors and autoimmune disorders. A live audio webcast will be available on atarabio.com, with a recorded version accessible for 30 days post-event.
Atara Biotherapeutics (Nasdaq: ATRA) has not yet initiated the Biologics License Application (BLA) for tab-cel® (tabelecleucel), under Phase 3 development for EBV-positive post-transplant lymphoproliferative disease. The Company awaits a procedural decision from the FDA regarding historical data presentation in the BLA. Despite the delay, Atara remains on track to complete the BLA filing in Q3 2021, with an objective response rate of 50% reported in the pivotal study. Ongoing discussions with the FDA are described as constructive.
FAQ
What is the current stock price of Atara Biotherapeutics (ATRA)?
What is the market cap of Atara Biotherapeutics (ATRA)?
What does Atara Biotherapeutics, Inc specialize in?
When was Atara Biotherapeutics founded?
Who is Atara Ciechanover?
What are some of Atara's key product candidates?
With which institution is Atara Biotherapeutics collaborating?
What types of T-cell therapies is Atara developing?
What is the mission of Atara Biotherapeutics?
Where does Atara Biotherapeutics operate?
What are activin and myostatin in the context of Atara's research?
How does Atara manage its business operations?
